Affiliation:
1. Department of Laboratory Medicine, Semmelweis University, 1089 Budapest, Hungary
2. 2nd Department of Pediatrics, Semmelweis University, 1094 Budapest, Hungary
Abstract
Orally administered, small-molecule anticancer drugs with tumor-specific cellular protein targets (OACD) have revolutionized oncological pharmacotherapy. Nevertheless, the differences in exposure to these drugs in the systemic circulation and extravascular fluid compartments have led to several cases of therapeutic failure, in addition to posing unknown risks of toxicity. The therapeutic drug monitoring (TDM) of OACDs in therapeutically relevant peripheral fluid compartments is therefore essential. In this work, the available knowledge regarding exposure to OACD concentrations in these fluid spaces is summarized. A review of the literature was conducted by searching Embase, PubMed, and Web of Science for clinical research articles and case reports published between 10 May 2001 and 31 August 2022. Results show that, to date, penetration into cerebrospinal fluid has been studied especially intensively, in addition to breast milk, leukocytes, peripheral blood mononuclear cells, peritoneal fluid, pleural fluid, saliva and semen. The typical clinical indications of peripheral fluid TDM of OACDs were (1) primary malignancy, (2) secondary malignancy, (3) mental disorder, and (4) the assessment of toxicity. Liquid chromatography–tandem mass spectrometry was most commonly applied for analysis. The TDM of OACDs in therapeutically relevant peripheral fluid spaces is often indispensable for efficient and safe treatments.
Reference148 articles.
1. McLaughlin, A.M., Schmulenson, E., Teplytska, O., Zimmermann, S., Opitz, P., Groenland, S.L., Huitema, A.D.R., Steeghs, N., Müller, L., and Fuxius, S. (2021). Developing a nationwide infratructure for therapeutic drug monitoring of targeted oral anticancer drugs: The ON-TARGET study protocol. Cancers, 13.
2. Kinase drug discovery 20 years after imatinib: Progress and future directions;Cohen;Nat. Rev. Drug Discov.,2021
3. Intrinsic and extrinsic pharmacokinetic variability of small molecule targeted cancer therapy;Reyner;Clin. Transl. Sci.,2020
4. Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology;Verheijen;Clin. Pharm. Ther.,2017
5. The effects of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia;Saydam;Int. J. Hematol. Oncol.,2022
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献